By Michael Dabaie

 

ESSA Pharma Inc. said Wednesday it is in a clinical trial collaboration and supply agreement with Bayer.

ESSA, a clinical-stage pharmaceutical company, said the agreement is to evaluate its lead product candidate, EPI-7386, in combination with Bayer's darolutamide in patients with metastatic castration-resistant prostate cancer.

Under the agreement, Bayer may sponsor and conduct a Phase 1/2 study. ESSA said it will supply EPI-7386 for the trial and will retain all rights to EPI-7386. The clinical study is expected to start in 2021.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

April 28, 2021 08:01 ET (12:01 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (XE:BAYN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Bayer Charts.
Bayer (XE:BAYN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Bayer Charts.